Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.

By D. Fliser, B. Kollerits, U. Neyer, D. Ankerst, K. Lhotta, A. Lingenhel, E. Ritz, F. Kronenberg, E. Kuen, P. König and 5 more. Journal of the American Society of Nephrology, 2007

728 citations recorded by the source corpus.

Subfields: Nephrology, Nutrition and Dietetics, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/e7aec1a7cfbbc07cbd95f989e8ad428f434354ad

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Nephrology

Citations in the corpus

FGF23, PTH and Phosphorus Metabolism in the Chronic Renal Insufficiency Cohort (2011, result): “associated with CKD progression, cardiovascular disease, and mortality in previous prospective studies of CKD patients.(9,13) Using an even more conservative threshold of X125 RU/ml to define FGF23 excess, 59% of participants qualified.”
Epidemiology of chronic kidney disease in children (2011, background): “Other factors potentially involved in the progression of CKD have been addressed in adult patients, including metabolic acidosis, anemia, altered calcium-phosphate homeostasis, chronic inflammation, and metabolic factors, such as diabetes, hyperuricemia, dyslipidemia, and smoking [70–75].”
Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients with Chronic Kidney Disease (2011, background): “However, small studies suggest that an elevated FGF-23 level is an independent risk factor for mortality among patients undergoing dialysis,(4,5) and for more rapid loss of kidney function in earlier stages of chronic kidney disease.(6,7) Whether FGF-23 is associated with greater risks of mortality ”
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) (2017, result): “among patients with CKD G3a to G5 or after transplantation (Supplementary Tables S49–S51, S53–S55), although some studies did not confirm this association.(49,50)”